Clinical trial NCT03711474
Conditions: Dysphagia
Sponsor: West Virginia University
Start date: 2018-09-07; Completion date: 2024-07-30
Enrollment: 78 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
This prospective, randomized, double blind, controlled study evaluates the effect of a single dose of perioperative IV steroid versus saline on swallowing after anterior cervical spine surgery

Detailed description:
This investigation is a prospective, randomized, double-blind, controlled trial testing a single dose of peri-operative steroid versus saline and the effect on swallowing after anterior cervical spine surgery.

Swallowing symptoms will be measured using the patient reported Bazaz (Bazaz) scale, the EAT10 survey, and the Dysphagia Short Questionnaire (DSQ). Swallowing data will be obtained pre-operatively, one day and two days post-operatively and then one week, two weeks, four weeks, three months, six months, and one year post-operatively. Patient clinical outcomes will be captured using web-based progress reports. Patients will complete the Quality of Life (QoL-12), Neck Disability Index (NDI), and Visual Analog Scale (VAS) questionnaires electronically pre-operatively and at one year post-operatively. This outcome data will help us analyze the swallowing function or symptoms with the overall clinical course of the patients enrolled in this study.

Arms: arm 1: Drug: Treatment 1; Dexamethasone. Patients undergoing elective anterior cervical spine surgery will be seen by spine surgeons. After consent the Bazaz, EAT 10 and Dysphagia Short Questionnaire will be administered at baseline prior to surgery, Day 1, Day 2, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months after surgery.

Patients will be randomized to either the single dose steroid administration group or the single dose saline administration group. Patients randomized to the experimental (steroid) group will receive a single dose, 0.3 mg/kg of body weight of intravenous dexamethasone within one hour of the incision. Patients in the control(saline) group will receive a single dose of saline, 0.3 mg/kg of body weight within one hour of incision. arm 2: Drug: Treatment 0; Saline placebo. Patients undergoing elective anterior cervical spine surgery will be seen by spine surgeons. After consent the Bazaz, EAT 10, and Dysphagia Short Questionnaire will be administered at baseline prior to surgery, Day 1, Day 2, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months after surgery.

Patients will be randomized to either the steroid administration group or the saline administration group. Patients randomized to the experimental (steroid) group will receive a single dose, 0.3 mg/kg of body weight of intravenous dexamethasone within one hour of the incision. Patients in the control(saline) group will receive a single dose of saline, 0.3 mg/kg of body weight within one hour of the incision.
Interventions: intervention 1: Dexamethasone intervention 2: Saline
Intervention descriptions: intervention 1: Single dose of Dexamethasone IV or Saline IV given within the first hour of surgery intervention 2: Single dose of Dexamethasone IV or Saline IV given within the first hour of surgery

Protocol documents:
Prot_SAP_000.pdf: 
 
Dysphagia Following Anterior Cervical Spine Surgery; Single Dose Steroid Vs Saline (DysDexVSSal) 
 
NCT03711474 
 
04DEC2019 


Human Subject Research
Does the protocol meet the federal definition of research? For help determining the type of research you are conducting, see the DHHR Human Subject 
Regulations Decision Charts at http://www.hhs.gov/ohrp/policy/checklists/decisioncharts.html.
Yes
Does the research involve living person(s)?
Yes
Will information from individual person(s) be collected as part of this research?
Yes
Funding Source
Is there a secured funding source?
No
Locations of Research
Select the location(s) where the research will be conducted. At least one location must be selected.
Ruby Memorial Hospital or Other WVU Healthcare Site
Select the location(s) where the research will be conducted. At least one location must be selected.
WVU Campus
Will the research take place at an off campus location?
No
Will this study require an Inter-Institutional Authorization Agreement (IAA)?
No
Design
Please provide a lay summary (written at 6th grade level) that includes a statement about the purpose and the general aims of the research.
Dysphagia (difficulty swallowing) is common following anterior cervical spine surgery. Studies have documented persistent swallowing difficulty up to 
two years postoperatively. The long term objective is to change the treatment paradigm for cervical spine surgery to minimize dysphagia and associated 
complications. The specific aims are to identify the effect of a single dose of perioperative steroid on dysphagia and to develop a treatment protocol for 
the frequency of perioperative steroids needed to reduce dysphagia. This is a prospective, randomized, placebo-controlled study. Patients will be given a 
single dose of dexamethasone or normal saline intratoperatively and then assessed at multiple time points up to one year. The research question is what is 
the effect of a single dose of perioperative steroid on dysphagia after anterior cervical spine surgery? The survey instruments used to determine difficulty 
swallowing include the Bazaz, Dysphagia Short Questionnaire, and EAT 10. To administer the Bazaz instrument, the study coordinator will ask the 
subject if he/she has difficulty swallowing liquid food and give the options 'none', 'rare', 'present all the time'. The options for solid food with are 'none', 
'rare', 'occasional only with specific foods', or 'frequent majority of solids'. The options on the left side of the questionnaire determine the level of 
difficulty. If a subject has no difficulty swallowing both liquid and solid food, 'none' will be chosen. The level of difficulty swallowing is determined by 
the highest difficulty, e.g. if a subject had no difficulty swallowing liquid food and has rare difficulty swallowing solid food, 'mild' will be chosen. If the 
subject has no difficulty swallowing liquid food but has frequent difficulty swallowing solid food, 'severe' will be chosen.
Fully describe all procedures to be performed, from start to finish, numbering your procedures 1,2,3 or A, B, C (e.g., 1. Recruiting, 2. Consent, 3. 
Collecting data, 4. How findings will be shared, etc.).
1.Potential subjects will see Drs. Daffner, France, Cui, Sedney or Emery at their visit prior to elective anterior cervical spine surgery at the Spine or 
Neurosurgery Clinic. 2. Subjects will be told about the study at this visit, all questions will be answered by the surgeons and the research coordinator, all 
surveys that need to be completed will be shown to the potential subjects and they will be given the opportunity to consent. 3. If consented, the subject 
will be asked to complete baseline surveys (Bazaz, EAT-10, and Dysphagia Short Questionnaire) at this visit. The subject will also complete Standard of 
Care Patient Reported Outcome Measures (PROMS) at this visit. 4. The subject will be randomized to receive either single dose steroid (dexamethasone) 
or saline (placebo) prior to surgery. The dose is calculated based on body weight group will receive 0.3 mg/kg of intravenous dexamethasone 
(experimental group) 0.3 mg/kg saline (control group). The subject will not be charged for dexamethasone or saline. 5. The subject will undergo anterior 
cervical spine surgery per standard of care. 6. After administration of the antibiotics in the operating room, the single dose of steroid or saline will be 
given by the anesthesia team, who are blinded to the group assignment, via an intravenous bag (study drug) prepared by the investigational pharmacist, 
the only person who knows the group assignment. 7. The surgeon, patient, and research team are blinded to the group assignment. 8. The subject will be 
administered the surveys by phone call or in the hospital by the research coordinator on Day 1. 9. On Day 2, if the subject is still hospitalized, surveys 
will be administered by the research coordinator in the hospital or via phone call. 10. Following Day one surveys, and if the subject has been discharged, 
the subject will be called to complete the answers to the surveys via phone call at Day 2, Week 1, Week 2, Month 1, Month 3, Month 6 and Month 12. At 
Month 12, the subject will be asked to also complete standard of care PROMS. If the subject is in the clinic for follow up at the designated time frame for 
survey administration, the surveys will be completed in the clinic. If the subject is not in clinic at Month 12, the PROMS will be completed via phone 
call. 10. At the end of the study, all subjects will be called or mailed a letter indicating the group assignment they had been in. 11. Study Results will not 
be shared with the subjects.
Please describe the investigational procedures that will be performed throughout the duration of the study.
Randomization to steroids or no steroids for anterior spinal fusion subjects and completion of the Bazaz, Short Dysphagia Questionnaire and EAT-10 
survey.
Please describe the standard of care procedures that will be performed throughout the duration of the study.
Page 2 of 8
Protocol Questionnaire
12/4/2019
https://kc.wvu.edu/kc/protocolQuestionnairePrint.do?protocolId=2629564


Everything outside of the randomization.
Will you be assigning or randomizing participants to groups or conditions (e.g., control, placebo)?
Yes
Describe the group assignment.
Random assignment to receive either one dose of steroid or one dose of saline (Placebo) during the first hour of surgery.
Does the research involve surveys/interviews/questionnaires? If so, attach a copy of the interview/survey questions on the Notes & Attachments page.
Yes
Will you be asking any questions that are likely to distress your subjects (e.g., questions about abuse, trauma, or suicide ideation)? If so, attach 
counseling services referral list on the Notes & Attachments page.
No
Describe what is known about this topic and why this study is needed. Please include at least two reference citations to support your rationale.
See lit review and scientific rationale under Notes and Attachments.
What method are you going to use to analyze the data?
Swallowing symptoms will be measured using the patient reported Bazaz Dysphagia Scale, EAT-10 survey, and the Dysphagia Short Questionnaire. 
Swallowing data will be obtained pre-operatively, one and two days post-operatively and then one week, two weeks, four weeks, three months, six 
months, and one year post-operatively. Scores from the Bazaz Dysphagia Scale and the Dysphagia Short Questionnaire from the two groups will be 
compared at the various time points using the Mann-Whitney U test. Power and sample size calculations are based on the presence or absence of 
dysphagia at two weeks. Based on a literature review, we postulated that 50% of the patients in the control group would experience mild, moderate, or 
severe dysphagia. If that figure can be improved to the point where just 20% of the patients are similarly affected then that, in our opinion, would 
represent clinical success. Under the above scenario, 32 patients in each group would give us 81% power to reject the null hypothesis. Assuming a 
dropout rate of 20% our total sample size for the study is 80. Statistical significance is set at p<0.05. We plan to analyze the data in three ways. First, we 
will look at the time-to-event where the event is "no dysphagia" in a discrete time survival model. Second, we will use a repeated measures ordinal 
categorical model to assess the effect of steroid/control in a generalized linear model. Lastly, we will compare the data from this study with that of our 
previous three-dose model to assess any difference in the degree of impact of the two dosing regimens.
Full Board Review Risk Assessment
Is this study more than minimal risk? (If NO, then this study should be submitted as an expedited protocol)
Yes
Does the study involve intervention and/or manipulation of the subjects or the subjects' environment (e.g., educational intervention or training, 
experimental or quasi-experimental design)?
Yes
Is the research categorized as interventional medical research?
Yes
Will monitoring for harms occur?
Yes
Describe monitoring for harm.
Please see the Data Safety Monitoring Plan under Notes and Attachments
Is there a Data and Safety Monitoring Plan (DSMP) for this study?
Yes
Is there a Data and Safety Monitoring Board (DSMB) for this study?
Yes
Is the DSMB independent?
No
Who will monitor the data?
The research team and Dr. Balcik, who is outside the department but serving on the DSMB.
What data will be monitored?
Adverse reaction to dexamethasone.
How frequently will data be monitored?
The board will meet after the first five subjects have had surgery. If no unexpected harms have been found, the board will meet every 3 months. Should 
an unexpected AE occur during the study, the board will be notified immediately and a decision will be made regarding continuing or discontinuing the 
study.
Describe how information relevant to the protection of participants will be managed addressing unanticipated problems involving risk to participants or 
others, interim results, and protocol modifications.
Should an unexpected AE occur during the study that is related to the research, the board will be notified immediately and a decision will be made 
regarding continuing or discontinuing the study.
Page 3 of 8
Protocol Questionnaire
12/4/2019
https://kc.wvu.edu/kc/protocolQuestionnairePrint.do?protocolId=2629564


Describe how the monitoring of data may ensure the safety of participants (e.g., a drastic blood pressure increase).
Dexamethasone may increase blood sugar in subjects with diabetes. All subjects with diabetes are carefully monitored for any rise in blood sugar per 
standard of care.
List all the standard medical, behavioral, and/or educational procedures that will be utilized.
The surgeries are standard of care as well as completion of patient reported outcomes at the time frames listed.
List the investigational interventions that will be utilized, above and beyond the standard of care.
Randomization to steroid or placebo; completion of Bazaz and the Short Dysphagia Questionnaire.
What decision rules (e.g., stopping rules) will be considered?
The board will meet after the first five subjects have had surgery. If no unexpected harms have been found, the board will meet every 3 months. Should 
an unexpected AE occur during the study, the board will be notified immediately and a decision will be made regarding continuing or discontinuing the 
study.
Will the protocol be stopped once harms are proven to outweigh benefits?
Yes
Will clinical findings be shared with the subjects?
Yes
Describe how findings will be shared with the subjects.
At the completion of the study all patients will be notified by phone call or letter their group assignment and results of the study.
Will incidental findings be shared with the subjects?
Yes
Will WVU's procedures on incidental findings be followed?
Yes
Describe how and where researchers will interact with participants, explaining how these interactions will be kept private.
Researchers will interact with participants in private rooms of the spine clinic and neurosurgery clinic at the participant's history and physical visit prior 
to elective anterior spine surgery. They will see participants in their hospital room Day 1 after surgery and possibly Day 2 if the participant remains in 
the hospital past day 1. They will ask participants to complete the Bazaz, EAT-10, and Dysphagia Short Questionnaire on Day 1 and Day 2. They will 
call participants from a private room to complete questionnaires should the subject not return for regularly scheduled follow up visits. They will interact 
with participants at their standard of care follow up visits in the clinic.
Describe any possibilities for risk or harm to the subjects as a result of their participation in the research (e.g., discomforts or hazards to the subjects). 
Please assess the severity of these risks.
The only inconvenience is answering questions on the surveys face to face or via a phone call. The subjects will have a full understanding of the time 
frames by which they will be contacted to anser questions before consenting. Subjects will not be recruited if they don't want to answer the survey 
questions during the time frames. There should be no discomfort with administration of the study drug.
Will subjects intentionally be deceived as to the purpose of the study?
No
HIPAA
Does the research involve protected health information (PHI)?
Yes
Will the HIPAA and consent forms be combined? If not, attach a separate HIPAA Authorization to the Notes & Attachments page.
Yes
Are you requesting a HIPAA waiver? If yes, attach a HIPAA Waiver Form on the Notes & Attachments page.
No
Will the research being conducted at a covered entity require authorization from the subject? If yes, attach a HIPAA Form on the Notes & Attachments 
page - only if a combined consent with HIPAA is not used.
No
Are you transferring identifiable data to or from another institution? If yes, attach a signed and WVU Legal Counsel approved HIPAA Data Use 
Agreement Form on the Notes & Attachments page.
No
Will the research being conducted at a covered entity involve data that is de-identified? If yes, attach a HIPAA De-Identification Certification Form on 
the Notes & Attachments page. You can find the form here (this is only for NHSR studies).
No
Will the study include deceased individuals? If yes, attach a HIPAA Decedents Form on the Notes & Attachments page.
No
Page 4 of 8
Protocol Questionnaire
12/4/2019
https://kc.wvu.edu/kc/protocolQuestionnairePrint.do?protocolId=2629564


Will data/samples with identifiers be received from another entity? If yes, attach a signed, Legal Counsel approved HIPAA Data Use Agreement Form 
on the Notes & Attachments page.
No
Subjects
Indicate the maximum number of subjects to be enrolled or medical records to be reviewed at all sites by the WVU or VAMC research team.
80
Provide a rationale for choosing your sample size.
Scores from the Bazaz scale, the EAT-10, and the Dysphagia Short Questionnaire from the two groups will be compared at the various time points using 
the Mann-Whitney U test. Statistical significance is set at p<0.05. With a power of 0.80 and a clinical meaningful difference of 30% in scores, an 
estimated 32 patients per group is needed. However, based on a recent unpublished study at our institution, we expect a dropout rate of approximately 
20%, and therefore plan for a total sample size for this study of 80 patients.
State the requirement(s) to become a participant in the study (e.g., age range, sex, language spoken, class enrollment/ranking).
Ages 18-80; undergoing elective ACDF, hybrid constructs, corpectomies, disc arthroplasty surgery
Explain why selection of participants will be equitable addressing gender, ethnicity, and/or race of subjects.
No one will be excluded based on gender, ethnicity or race. Exclusion criteria include: < 18 years of age; major trauma or neoplastic or infectious 
conditions requiring surgery. Also excluded will be patients undergoing anterior-posterior operations, those with a history of previous anterior cervical 
spine surgery, any patient requiring a halo vest, patients on chronic steroids, and patients remaining intubated post-operatively, and women who are 
pregnant.
In outline format and chronological order, describe what will be done to identify and recruit participants (e.g., A, B, C or 1, 2, 3).
1. Potential subjects will see Drs. Daffner, France, Cui, Emery or Sedney at their History and Physical visit prior to elective anterior cervical spine 
surgery at the Spine Center. 2. Subjects will be told about the study at this visit, all questions will be answered by the surgeons and the research 
coordinator, all surveys that need to be completed will be shown to the potential subjects and they will be given the opportunity to consent. 3. If 
consented, the subject will be asked to complete baseline surveys (Bazaz, EAT-10 and Dysphagia Short Questionnaire) at this visit. 4. The subject will 
be randomized to receive either single dose steroid (dexamethasone) or saline (placebo) prior to surgery.
Will any of the subjects be less than 18 years old?
No
Will your study target populations such as pregnant women, fetuses, neonates, or any groups likely to be vulnerable to coercion or undue influence such 
as children, prisoners, individuals with impaired decision-making capability or economically or educationally disadvantaged persons?
No
Does this research involve participants who could be coerced or unduly influenced, such as current students/employees of research team members?
No
Does the protocol deal with cancer prevention, treatment, or diagnosis (including surveys)?
No
Has this protocol been reviewed by Clinical Trials Working Group (CTWG)? If yes, please attach the CTWG's correspondence on the Notes & 
Attachments page.
No
Consent Procedures
Will SIGNED informed consent be obtained from subjects (all or in part)?
Yes
Will the informed consent form be translated into any other language(s)?
No
Is a waiver of informed consent being requested (i.e., there will be no consent process at all)?
No
Is a waiver of the requirement to obtain written documentation of the consent process being requested (if yes, attach the information to be provided to the 
participants)?
No
Are you requesting an alteration of consent (e.g., short form, braille consent or witnessed verbal consent)?
No
Describe the consent process (using 1, 2, 3 or A, B, C), addressing when, where, and how participants will be informed.
Potential participants will be told of the study in the Spine or Neurosurgery Clinic in a private room during their History and Physical visit prior to 
surgery. A research team member will inform the subject about the study, answer all their questions, show them the surveys and the subject will be given 
the opportunity to consent.
Indicate who will be consenting subjects and describe the process of training all personnel who will be obtaining consent.
Page 5 of 8
Protocol Questionnaire
12/4/2019
https://kc.wvu.edu/kc/protocolQuestionnairePrint.do?protocolId=2629564


Research team members including research coordinators who have been consenting patients for years.
Potential Benefits
Is there any known benefit to the individual subject as a result of participating in the research? Payments to subjects should not be included in this 
section, but addressed in the Payments/Reimbursements section.
Potential benefit is less difficulty swallowing if the subject is assigned to the steroid group.
Describe the potential benefit(s) to society and/or scientific / medical knowledge of the planned work.
The results of this study will provide evidence for the use of steroids as a treatment for reducing the incidence and severity of dysphagia among patients 
undergoing anterior cervical spine surgery. A recently performed study at our institution has promising results from a three-dose regimen of steroids. 
Similarly, two recent clinical studies have also shown decreased dysphagia with a multi-dose steroid regimen. If the hypothesis of this proposal is 
supported, the use of a single dose of perioperative steroid specifically lends itself well to application in patients undergoing these procedures in 
outpatient surgery centers, improving the safety of such procedures.
Confidentiality
At any point during this study, will identifiable data be viewed or recorded?
Yes
Data must be kept for a minimum of three (3) years after study completion. In addition to the required 3 years, how much longer will the data be kept?
Three years after study completion.
Where will data be securely located?
In REDCAP, on the password protected computer of a research team member in the Department of Orthopaedics.
How will data be destroyed?
It will be erased from the password protected computer.
Will anyone other than the PI, research team members, or IRB have access to the identifiable data (e.g., sponsor/funding source, other collaborators)?
No
Describe the steps that will be taken to maintain the privacy of subjects (e.g., where interaction takes place) and the confidentiality of data (e.g., master 
code).
1.Potential subjects will see Drs. Daffner, France, Cui, Emery or Sedney at their History and Physical visit prior to elective anterior cervical spine 
surgery in a private room at the Spine Center. 2. Subjects will be told about the study at this visit, all questions will be answered by the surgeons and the 
research coordinator, all surveys that need to be completed will be shown to the potential subjects and they will be given the opportunity to consent. 3. If 
consented, the subject will be asked to complete baseline surveys (Bazaz, EAT-10 and Dysphagia Short Questionnaire) at this visit. 4. The subject will 
be randomized to receive either single dose steroid (dexamethasone) or saline (placebo) prior to surgery. 5. The subject will be seen post-op day one by 
the research coordinator (and post op Day 2 if the subject is still hospitalized) who will administer the surveys in the hospital room. 6. Following Day 
one surveys, and after discharge, the subject will be called from a private room of a research coordinator to complete the answers to the surveys via 
phone call at Day 2, Week 1, Week 2, Month 1, Month 3, Month 6 and Month 7. If the subject is in the clinic for follow up at the designated time frame 
for survey administration, the surveys will be completed in a private room in the clinic.
Does this study have a Federal Certificate of Confidentiality? If yes, attach the certificate on the Notes & Attachments page.
No
Financial Considerations
Will the subjects incur any costs to participate in this project (e.g., travel, physician fees, study procedures, study drugs)?
No
Will the subject be paid (money, gift certificates, coupons, etc.) to participate in this research project?
No
Will WVU students receive extra credit for participating in this research project?
No
Advertisements
Will there be advertisements for this study?
No
Drug/Substance/Nutrient/Biologic
Are there any drugs/substances/nutrients/biologics being used in this research study for investigational/research purposes ONLY?
Yes
Enter the name of the first drug being used for investigational/research purposes ONLY.
dexamethasone
Page 6 of 8
Protocol Questionnaire
12/4/2019
https://kc.wvu.edu/kc/protocolQuestionnairePrint.do?protocolId=2629564


Is this an Investigational New Drug (IND) (if so, please attach the investigator brochure or applicable documentation)?
No
Is this drug/substance/nutrient/biologic being used off-label (if so, please attach the package insert or applicable documentation)?
No
Does this drug/substance/nutrient/biologic meet the requirements of an IND exemption? The clinical investigation of a marketed drug or biologic does 
not require submission of an IND if all six (6) exemption conditions are met.
No
Is there a second drug/substance/nutrient/biologic used in this research study for investigational/research purposes ONLY?
No
Provide any other information regarding the drugs/substances/nutrients/biologics being used in this study that is relevant to the IRB review.
Dexamethasone is a commonly used drug administered by anesthesiologists when patients are having difficulty swallowing after surgery or to reduce 
nausea and vomiting.
Will all drugs/substances/nutrients/biologics being used in this study be provided free of charge?
Yes
Will all drugs/substances/nutrients/biologics being used in this study be stored at the WVU Healthcare Pharmacy (WVUHP)? All drug storage must be 
approved by the WVUHP.
Yes
Will there be any drugs/substances/nutrients/biologics used in this study NOT for investigational/research purposes?
No
Device Information
Are there investigational devices that will be used in this study?
No
Sample Collection
Will sample(s) be used?
No
Radiation Safety
Will there be any radioactive materials or ionizing radiation used solely for research in this study?
No
Biological Safety
Does the study involve the handling of any infectious and/or non-infectious agents or recombinant DNA?
No
Data Protection for IRB
Does the project have data protection requirements?
No
Protocol Notes
DATE
AUTHOR
TOPIC
NOTE
06/25/2019 
03:48 PM
Sherri 
Davis
A003
Removing Hanna Jiles from study personnel, and adding Olivia Hill and Skylar Braga to study 
personnel to assist with data entry.
06/19/2019 
11:43 AM
Sherri 
Davis
Response to Spec 
Min Rev R001
*Please include clinicaltrials.gov language in the consent form. Please find the requested 
language in the consent form on page three, the last paragraph of the confidentiality section.
Renewal 001
Renewing protocol with 17 subjects to date. DSMB reports filed. No SAEs to report.
Page 7 of 8
Protocol Questionnaire
12/4/2019
https://kc.wvu.edu/kc/protocolQuestionnairePrint.do?protocolId=2629564


06/05/2019 
03:55 PM
Sherri 
Davis
Page 8 of 8
Protocol Questionnaire
12/4/2019
https://kc.wvu.edu/kc/protocolQuestionnairePrint.do?protocolId=2629564

ICF_001.pdf: 
 
Dysphagia Following Anterior Cervical Spine Surgery; Single Dose Steroid Vs Saline (DysDexVSSal) 
 
NCT03711474 
 
09MAR2022 


Human Research Protocol 
More Than Minimal Risk Form 
(With HIPAA) 
Phone: 304-293-7073 
Fax: 304-293-3098 
http://oric.research.wvu.edu 
Chestnut Ridge Research Building 
886 Chestnut Ridge Road 
PO Box 6845 
Morgantown, WV 26506-6845 
P a g e  | 1 
Subject’s 
Initials_________________ 
Date_________________ 
More Than Minimal Risk 
Consent and HIPAA Form 
Principal Investigator 
Scott Daffner, MD 
Department 
 
Orthopaedics 
Protocol Number 
1804077978 
Study Title 
Impact of Single Dose Perioperative Steroids on Dysphagia Following Anterior 
Cervical Spine Surgery: A Randomized, Prospective, Double-Blind Study 
Co-Investigator(s) 
 
Sanford Emery, MD; John France, MD; Shari Cui, MD; Cara Sedney, MD; 
Robert Marsh, MD; Sanjay Bhatia, MD 
Study Personnel 
Paige Harman, Patricia Dekeseredy, Jenn Eicher 
Contact Persons 
In the event you experience any side effects or injury related to this research, you should contact Dr. Scott Daffner at 
(304) 293-2779. (After hours contact WVU Healthcare at 304-598-4000 and ask for the Orthopaedic resident on call.)  If
you have any questions, concerns, or complaints about this research, you can contact Dr. Scott Daffner (304) 293-2779.
For information regarding your rights as a research subject, to discuss problems, concerns, or suggestions related to the 
research, to obtain information or offer input about the research, contact the Office of Research Compliance at (304) 
293-7073.
Introduction 
You, ______________________, have been asked to participate in this research study, which has been explained to you 
by _______________________________________________________. This study is being conducted by Scott Daffner, 
MD; Sanford Emery, MD, MBA, John France, MD, Shari Cui, MD, in the Department of Orthopaedics, and Cara Sedney, 
MD; Robert Marsh, MD; Sanjay Bhatia, MD, in the Department of Neurosurgery at West Virginia University. 
Purpose(s) of the Study 
The purpose of this study is to find out if giving one dose of steroid during cervical spine surgery helps reduce difficulty 
swallowing (dysphagia) after surgery.    
WVU expects to enroll approximately 80 subjects.  
Approved:9-Mar-2022Expires:8-Mar-2023Number:1804077978


 
Human Research Protocol 
More Than Minimal Risk Form 
(With HIPAA) 
 
 
Phone: 304-293-7073 
Fax: 304-293-3098 
http://oric.research.wvu.edu 
Chestnut Ridge Research Building 
886 Chestnut Ridge Road 
PO Box 6845 
Morgantown, WV 26506-6845 
 
 
P a g e  | 2 
 
Subject’s 
Initials_________________ 
Date_________________ 
 
 
 
 
Description of Procedures 
This study involves randomization (like flipping a coin) to either the group receiving a single dose of steroid during 
surgery or the group receiving a single dose of saline during surgery.  This is a double blind study, which means the 
surgeon, anesthesiologist, and the patient will not know what group assignment (saline or steroid) the patient has 
received.  The in-patient pharmacy will prepare IV bags that are labeled for the study but that are blinded as to 
medication/saline labels.   
 
You will receive one dose of the study drug during surgery.  You will be asked to fill out three short surveys regarding 
swallowing difficulties; the Bazaz dysphagia scale, the Dysphagia Short Questionnaire and the E-10 survey. This will take 
approximately 5 minutes to complete.  You do not have to answer all the questions.  You will have the opportunity to 
see the questionnaires before signing this consent form.  You will also be asked to complete standard of care 
questionnaires via a tablet computer or via email at the visit before your surgery and at 1 year post-surgery.  The 
questionnaires allow us to determine how you are doing before and after surgery.  They are Patient Reported Outcome 
Measures (PROMS).  It will take you approximately 15 minutes to complete the PROMS.   
Both groups will be asked to complete the short surveys before their surgery and postoperatively at Day 1, Day 2, Week 
1, Week 2, Month 1, 3, 6, and 12.  On Day 2 after surgery, if you are discharged, the surveys will be done via phone call.  
If you are still in the hospital, the Research Coordinator will come to your room and have you complete the surveys or 
call you.  At Week 1, you will also receive a phone call to compete the surveys as you will have no follow up visit 
scheduled at that time.  You may receive phone calls for all the following follow up times, Week 2, months 1, 3, 6, and 12 
to complete the surveys if the follow up visit is not scheduled at the time the surveys should be completed. We will 
evaluate which patients fare better regarding prevalence and severity of dysphagia (difficulty swallowing); those who 
have been administered steroid or those who have been administered saline, by analyzing the results from the surveys 
and reviewing medical records.  
Risks and Discomforts 
Dexamethasone, the steroid used in this study, may cause a possible elevation of serum glucose levels in diabetic 
patients.  All patients in the study are monitored after surgery with routine postoperative laboratory testing. An 
elevation of serum glucose levels would be detected and treated during routine monitoring. This study may involve risks 
to the unborn child. For this reason, women who are pregnant will not be accepted.  If you are a woman who could 
become pregnant, you will not be allowed to participate in this study until you have had a pregnancy test and the test 
has indicated that you are not pregnant. You must use a medically approved method of birth control through the day of 
surgery. 
Alternatives 
You do not have to participate in this study. 
Approved:9-Mar-2022Expires:8-Mar-2023Number:1804077978


 
Human Research Protocol 
More Than Minimal Risk Form 
(With HIPAA) 
 
 
Phone: 304-293-7073 
Fax: 304-293-3098 
http://oric.research.wvu.edu 
Chestnut Ridge Research Building 
886 Chestnut Ridge Road 
PO Box 6845 
Morgantown, WV 26506-6845 
 
 
P a g e  | 3 
 
Subject’s 
Initials_________________ 
Date_________________ 
 
 
 
An alternative is to seek a hospital that routinely gives steroids to patients undergoing anterior, cervical spine surgery, as 
this is standard of care for some hospitals.   
Benefits 
Possible benefits that may result from your participation include the improvement of your health, but since it is not 
known whether either therapy will be effective in your case, you may not receive any benefit or your condition may 
worsen.  The knowledge gained from this study may eventually benefit others. 
Financial Considerations 
You may wish to consult your insurance carrier prior to entering this study. 
 
There are no special fees for participating in this study, but any expense associated with current therapy or treatment of 
side effects will be billed to you or to your insurance company. 
Voluntary Compensation 
If you are injured as a result of this research, treatment will be available.  Responsibility for this treatment will be borne 
by you. In the event that you are physically injured as a result of participating in this research, care will be available. You 
will however, be responsible for the charges for the care. There is no commitment to provide any compensation for 
research-related injury. You should realize, however, that you have not released this institution from liability for 
negligence. Please contact the investigator, Scott Daffner at (304-293-2779) if you are injured or for further information. 
Confidentiality 
Any information about you that is obtained as a result of your participation in this research will be kept as confidential as 
legally possible.  Your research records and test results, just like hospital records, may be subpoenaed by court order or 
may be inspected by the study sponsor or federal regulatory authorities (including the FDA if applicable) without your 
additional consent. 
 
In addition, there are certain instances where the researcher is legally required to give information to the appropriate 
authorities.  These would include mandatory reporting of infectious diseases, mandatory reporting of information about 
behavior that is imminently dangerous to your child or to others, such as suicide, child abuse, etc. 
 
A description of this clinical trial will be available on www.ClinicalTrials.gov, as required by US law. This website will not 
include information that can identify you. At most, the website will include a summary of the results. You can search this 
website at any time. 
HIPAA  
Approved:9-Mar-2022Expires:8-Mar-2023Number:1804077978


 
Human Research Protocol 
More Than Minimal Risk Form 
(With HIPAA) 
 
 
Phone: 304-293-7073 
Fax: 304-293-3098 
http://oric.research.wvu.edu 
Chestnut Ridge Research Building 
886 Chestnut Ridge Road 
PO Box 6845 
Morgantown, WV 26506-6845 
 
 
P a g e  | 4 
 
Subject’s 
Initials_________________ 
Date_________________ 
 
 
 
We know that information about you and your health is private. We are dedicated to protecting the privacy of that 
information. Because of this promise, we must get your written authorization (permission) before we may use or 
disclose your protected health information or share it with others for research purposes. 
You can decide to sign or not to sign this authorization section. However, if you choose not to sign this authorization, 
you will not be able to take part in the research study. Whatever choice you make about this research study will not 
have an effect on your access to medical care. 
Persons/Organizations Providing the Information 
Patient/West Virginia University Hospitals 
Persons/Organizations Receiving the Information 
• 
The research site(s) carrying out this study.  This includes UHA or UHA Affiliated, WVU, WVU Hospitals.  It also 
includes each site’s research staff and medical staff 
• 
Health care providers who provide services to you as part of this research study. 
• 
Laboratories and other people and groups that look into your health information as part of this study in 
agreement with the study protocol. 
• 
The United State Department of Health and Human Services (which includes the National Institutes of Health 
(NIH), Food and Drug Administration (FDA)) and other groups that have the right to use the information as required by 
law. 
• 
The members and staff of any Institutional Review Board (IRB) that oversees this research study. 
• 
West Virginia University Office of Research Compliance and Office of Sponsored Programs. 
The Following Information Will Be Used 
Information from your existing medical records and new information about you that is created or collected during the 
study such as: history and physicals, clinic visit notes, nursing and staff notes, laboratory results, x-rays, EKG results, 
demographic data, pulmonary tests, imaging scans and study forms. 
The Information is Being Disclosed for the Following Reasons  
• 
Publication of study results (without identifying you) 
• 
Other research purposes such as reviewing the safety or effectiveness of the study drug; developing a better 
understanding of anterior, cervical spine surgery and dysphagia  
You May Cancel this Authorization at Any Time by Writing to the Principal Investigator 
Dr. Scott Daffner, West Virginia University, Department of Orthopaedics, 3400 Health Science Center South, 
Morgantown, WV  26506-9196 
Approved:9-Mar-2022Expires:8-Mar-2023Number:1804077978


 
Human Research Protocol 
More Than Minimal Risk Form 
(With HIPAA) 
 
 
Phone: 304-293-7073 
Fax: 304-293-3098 
http://oric.research.wvu.edu 
Chestnut Ridge Research Building 
886 Chestnut Ridge Road 
PO Box 6845 
Morgantown, WV 26506-6845 
 
 
P a g e  | 5 
 
Subject’s 
Initials_________________ 
Date_________________ 
 
 
 
If you cancel this authorization, any information that was collected already for this study cannot be withdrawn. 
Once information is disclosed, according to this authorization, the recipient may re-disclose it and then the 
information may no longer be protected by federal regulations. 
You have a right to see and make copies of your medical records. You will not be able to see or copy your 
records related to the study until the sponsor has completed all work related to the study. At that time you may 
ask to see the study doctor’s files related to your participation in the study and have the study doctor correct 
any information about you that is wrong. 
This authorization will expire at the end of the study unless you cancel it before that time (or has a specific 
expiration date). 
 
Voluntary Participation 
Participation in this study is voluntary.  You are free to withdraw your consent to participate in this study at any time. 
 
Refusal to participate or withdrawal will not affect [your class standing or grades, as appropriate] and will involve no 
penalty to you.  Refusal to participate or withdrawal will not affect your future care, or your employee status at West 
Virginia University. 
In the event new information becomes available that may affect your willingness to participate in this study, this 
information will be given to you so that you can make an informed decision about whether or not to continue 
your participation. 
 
You have been given the opportunity to ask questions about the research, and you have received answers 
concerning areas you did not understand. 
 
Upon signing this form, you will receive a copy. 
 
I willingly consent to participate in this research. 
Signatures 
Signature of Subject 
______________________________________________________________________________ 
Printed Name                                                                                Date                           Time 
______________________________________________________________________________ 
 
The participant has had the opportunity to have questions addressed.  The participant willingly 
agrees to be in the study. 
 
Approved:9-Mar-2022Expires:8-Mar-2023Number:1804077978


 
Human Research Protocol 
More Than Minimal Risk Form 
(With HIPAA) 
 
Phone: 304-293-7073 
Fax: 304-293-3098 
http://oric.research.wvu.edu 
Chestnut Ridge Research Building 
886 Chestnut Ridge Road 
PO Box 6845 
Morgantown, WV 26506-6845 
 
 
P a g e  | 6 
 
Subject’s 
Initials_________________ 
Date_________________ 
 
 
 
Signature of Investigator or Co-Investigator 
______________________________________________________________________________ 
Printed Name                                                                                Date                           Time             
______________________________________________________________________________ 
Approved:9-Mar-2022Expires:8-Mar-2023Number:1804077978